Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study

Lancet

Volumn 357, Issue 9267, 2001, Pages 1467-1470

  Narod, Steven A ^a   Sun, Ping ^a   Ghadirian, Parviz ^a,b   Lynch, Henry ^a,c   Isaacs, Claudine ^a,d   Garber, Judy ^a,e   Weber, Barbara ^a,f   Karlan, Beth ^a,g   Fishman, David ^a,h   Rosen, Barry ^a,i   Tung, Nadine ^a,j   Neuhausen, Susan L ^k  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j Beth Israel Deaconess Hospital   (United States)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ANAMNESIS; ARTICLE; BREAST CARCINOMA; CANADA; CANCER RISK; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OVARY CARCINOMA; PARITY; PREGNANCY; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES; UTERINE TUBE LIGATION;

EID: 0035849283     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04642-0     Document Type: Article

References (21)

1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCAl-mutation carriers. Lancet 1994; 343: 692-95.
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89.
3. Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001; 68: 410-19.
4. Risch HA, Mclaughlin JR, Vesprini DJ, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-11.
5. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II: BRCA1 and BRCA2. J Am Med Assoc 1997; 277: 997-1003.
6. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 424-28.
7. Jacobs IJ, Skates SJ, Macdonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-10.
8. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy and the risk of ovarian cancer. J Am Med Assoc 1993; 270: 2813-18.
9. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies, II: invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184-203.
10. Rosenblatt KA, Thomas DB, and WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. Cancer Epidemiol Biomarkers Prevent 1996; 5: 933-35.
11. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis in 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66: 1259-72.
12. Rilman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinal 1998; 49: 695-70.
13. Peterson HB, Jeng G, Folger SG et al. The risk of menstrual abnormalities after tubal sterilization. N Engl J Med 2001; 343: 1681-87.
14. Ness RB, Cottreay C. Possible role of ovarian inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91: 1459-67.
15. Gertig DM, Hunter DJ, Cramer DW, et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 2000; 92: 249-52.
16. Risch HA, Howe GR. Pelvic inflammatory disease and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 447-51.
17. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997; 176: 572-79.
18. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over the counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 104-07.
19. Cramer DW, Liberman RF, Hornstein MD, et al. Basal hormone levels in women who use acetaminophen for menstrual pain. Fertile Steril 1998; 70: 371-73.
20. Green A, Purdie F, Green L, Dick ML, Bain C, Siskind V. Validity of self-reported hysterectomy and tubal sterilisation. Aust N Z J Public 1997; 21: 337-40.
21. Brinton LA, Gammon MD, Coates RJ, Hoover RN. Tubal ligation and risk of breast cancer. Br J Cancer 2000; 82: 1600-04.